pioglitazone

Pioglitazone (U 72107) is a PPARγ agonist with EC50 of 0.93 and 0.99 μM on human and mouse PPARγ, respectively, and has selective and oral activity. Pioglitazone can be used in diabetes research.

Pioglitazone hydrochloride (AD 4833) is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Pioglitazone D4 is a deuterium labeled Pioglitazone. Pioglitazone is a agonist of PPARγ .

Pioglitazone potassium (U 72107) is an orally active, selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), exhibiting high-affinity binding to the ligand-binding domain of PPARγ with EC50 values of 0.93 μM for human and 0.99 μM for mouse PPARγ. It has applications in diabetes research [2] [3] [4].

(R)-Pioglitazone ((+)-pioglitazone), the R enantiomer of Pioglitazone, serves as a selective and orally active peroxisome proliferator-activated receptor (PPARγ) agonist. It exhibits high-affinity binding to the PPARγ ligand-binding domain and is utilized in research related to Alzheimers disease.

Hydroxy Pioglitazone M-IV-d4 is a deuterated compound of Hydroxy Pioglitazone M-IV.

Keto Pioglitazone-d4 is a deuterated compound of Keto Pioglitazone. Keto Pioglitazone has a CAS number of 146062-45-5. Ketopioglitazone is an active metabolite of pioglitazone.

Pioglitazone hydrochloride (Standard) is the standard substance of Pioglitazone hydrochloride, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Pioglitazone hydrochloride (AD 4833) is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.

Ketopioglitazone is an active metabolite of pioglitazone.

Leriglitazone, a metabolite of pioglitazone, binds to the PPARγ C-terminal ligand-binding domain (Ki: 1.2 μM) and induces transcriptional efficacy of the PPARγ (EC50: 680 nM). Leriglitazone PioOH is a PPARγ agonist, stabilizes the PPARγ activation functio

DRX-065 is a stabilized and deuterated R-enantiomer of pioglitazone. DRX-065 has pharmacological properties desirable for the treatment of NASH (mitochondrial function modulation, non-steroidal anti-inflammatory effects, and glucose lowering effects) with

Leriglitazone (Hydroxypioglitazone) hydrochloride, a pioglitazone metabolite, acts as a PPARγ agonist, effectively stabilizing the PPARγ activation function-2 (AF-2) co-activator binding surface to enhance co-activator binding, which results in a modest improvement in transcriptional efficacy. It binds to the PPARγ C-terminal ligand-binding domain (LBD) with a dissociation constant (K i) of 1.2 μM and demonstrates transcriptional efficacy with an effective concentration (EC 50) of 680 nM [1].